Focused On-demand Library for Elongation factor-like GTPase 1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q7Z2Z2

UPID:
EFL1_HUMAN

ALTERNATIVE NAMES:
Elongation factor Tu GTP-binding domain-containing protein 1; Elongation factor-like 1; Protein FAM42A

ALTERNATIVE UPACC:
Q7Z2Z2; A6NKY5; B7Z6I0; Q9H8Z6

BACKGROUND:
The protein Elongation factor-like GTPase 1, with alternative names such as Elongation factor Tu GTP-binding domain-containing protein 1, Elongation factor-like 1, and Protein FAM42A, is pivotal in ribosomal function and protein synthesis. It triggers the GTP-dependent release of EIF6, enabling the assembly of 80S ribosomes and promoting translation competence. Its activity is crucial for the processing and export of 60S rRNA to the nucleus, underscoring its role in cellular protein production.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Shwachman-Diamond syndrome 2, a disorder marked by severe hematopoietic, pancreatic, and skeletal abnormalities, Elongation factor-like GTPase 1 represents a significant target for drug discovery. Exploring the therapeutic potential of targeting Elongation factor-like GTPase 1 could lead to innovative treatments for this challenging genetic condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.